Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III StudyKim Papp, Woori Ko, Mark Lebwohl et al.|BioDrugs|2023Cited by 30
Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 studyChristian Buske, Michinori Ogura, Jin Seok Kim et al.|Blood Advances|2021Cited by 9